Literature DB >> 21686528

Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.

S Vulliemoz1, G Vanini, A Truffert, C Chizzolini, M Seeck.   

Abstract

Anti-glutamic acid decarboxylase (GAD) antibodies are described in stiff-person syndrome and also in other neurological syndromes, including cerebellar ataxia and epilepsy. This paper reports the case of a patient who had chronic focal epilepsy, upbeat nystagmus and cerebellar ataxia, associated with a polyautoimmune response including anti-GAD antibodies. Both gait and nystagmus improved markedly after immunosuppressive treatment with corticosteroids and azathioprine. After the introduction of benzodiazepines, previously refractory seizures were completely controlled. Anti-GAD antibodies should be actively sought out in pharmacoresistant epilepsy, particularly if other neurological abnormalities are present. Combined treatment with immunosuppressants and γhydroxybutyric acidergic agents may be highly effective.

Entities:  

Year:  2009        PMID: 21686528      PMCID: PMC3029780          DOI: 10.1136/bcr.09.2008.0977

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Excellent response to steroid treatment in anti-GAD cerebellar ataxia.

Authors:  Giuseppe Lauria; Davide Pareyson; Maria Giuseppina Pitzolu; Elena Bazzigaluppi
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

2.  Improvement of stiff-man syndrome with vigabatrin.

Authors:  M C Prevett; P Brown; J S Duncan
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

3.  Anti-GAD antibodies and periodic alternating nystagmus.

Authors:  Caroline Tilikete; Alain Vighetto; Paul Trouillas; Jérome Honnorat
Journal:  Arch Neurol       Date:  2005-08

4.  The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.

Authors:  Marinos C Dalakas
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

5.  Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.

Authors:  J Peltola; P Kulmala; J Isojärvi; A Saiz; K Latvala; J Palmio; K Savola; M Knip; T Keränen; F Graus
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

6.  Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus.

Authors:  T Lohmann; M Hawa; R D Leslie; R Lane; J Picard; M Londei
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

7.  Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study.

Authors:  P Kwan; G J Sills; K Kelly; E Butler; M J Brodie
Journal:  Epilepsy Res       Date:  2000-12       Impact factor: 3.045

8.  Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase.

Authors:  S F Kash; R S Johnson; L H Tecott; J L Noebels; R D Mayfield; D Hanahan; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

9.  Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.

Authors:  J Honnorat; A Saiz; B Giometto; A Vincent; L Brieva; C de Andres; J Maestre; N Fabien; A Vighetto; R Casamitjana; C Thivolet; B Tavolato; J Antoine; P Trouillas; F Graus
Journal:  Arch Neurol       Date:  2001-02

10.  Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus.

Authors:  G Antonini; R Nemni; F Giubilei; F Gragnani; V Ceschin; S Morino; E Bucci; N Accornero
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

View more
  2 in total

1.  An anti-GAD autoantibody-associated cerebellar syndrome case: a curable cause of ataxia.

Authors:  Vasfiye Burcu Dogan
Journal:  Neurol Sci       Date:  2015-06-10       Impact factor: 3.307

Review 2.  Anti-glutamic acid decarboxylase antibody positive neurological syndromes.

Authors:  Hassaan Tohid
Journal:  Neurosciences (Riyadh)       Date:  2016-07       Impact factor: 0.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.